{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:10:16Z","timestamp":1776820216133,"version":"3.51.2"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00103-022-03504-3","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T08:02:46Z","timestamp":1647849766000},"page":"420-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["K\u00f6rperliche Langzeitfolgen von Krebserkrankungen","Physical long-term consequences of cancer"],"prefix":"10.1007","volume":"65","author":[{"given":"Lisa","family":"Ernst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"3504_CR1","volume-title":"Bericht zum Krebsgeschehen in Deutschland 2016","author":"RKI","year":"2016","unstructured":"RKI (2016) Bericht zum Krebsgeschehen in Deutschland 2016. Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut, Berlin"},{"key":"3504_CR2","volume-title":"Datenbankabfrage mit Sch\u00e4tzung der Inzidenz, Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten","author":"RKI","year":"2021","unstructured":"RKI (2021) Datenbankabfrage mit Sch\u00e4tzung der Inzidenz, Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten"},{"issue":"3","key":"3504_CR3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1053-4296(03)00024-9","volume":"13","author":"NM Aziz","year":"2003","unstructured":"Aziz\u00a0NM, Rowland\u00a0JH (2003) Trends and advances in cancer survivorship research: challenge and opportunity1 1the ongoing need for research among long-term survivors of cancer is identified as a\u00a0key initiative within the new cancer survivorship extraordinary opportunity for research investment\u2014FY 2004 bypass budget of the national cancer institute. Semin Radiat Oncol 13(3):248\u2013266","journal-title":"Semin Radiat Oncol"},{"key":"3504_CR4","doi-asserted-by":"crossref","first-page":"S1174","DOI":"10.1016\/j.annonc.2021.08.1641","volume":"32","author":"ME Schmidt","year":"2021","unstructured":"Schmidt\u00a0ME, Hermann\u00a0S, Steindorf\u00a0K (2021) 1669O Late effects, long-term problems, and unmet needs of cancer survivors. Ann Oncol 32:S1174","journal-title":"Ann Oncol"},{"issue":"1","key":"3504_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00761-018-0501-1","volume":"25","author":"K Kraywinkel","year":"2019","unstructured":"Kraywinkel\u00a0K, Spix\u00a0C (2019) Epidemiologie prim\u00e4rer Hirntumoren bei Kindern und Erwachsenen in Deutschland. Onkologe 25(1):5\u20139","journal-title":"Onkologe"},{"issue":"2","key":"3504_CR6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/biof.1726","volume":"47","author":"TC Theoharides","year":"2021","unstructured":"Theoharides\u00a0TC, Cholevas\u00a0C, Polyzoidis\u00a0K, Politis\u00a0A (2021) Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue. Biofactors 47(2):232\u2013241","journal-title":"Biofactors"},{"issue":"1","key":"3504_CR7","first-page":"18","volume":"8","author":"M Alemany","year":"2021","unstructured":"Alemany\u00a0M, Velasco\u00a0R, Sim\u00f3\u00a0M, Bruna\u00a0J (2021) Late effects of cancer treatment: consequences for long-term brain cancer survivors. Neurooncol Pract 8(1):18\u201330","journal-title":"Neurooncol Pract"},{"issue":"6","key":"3504_CR8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff\u00a0NP, Grisold\u00a0A, Grisold\u00a0W, Windebank\u00a0AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772\u2013781","journal-title":"Ann Neurol"},{"issue":"11","key":"3504_CR9","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1007\/s00520-012-1418-7","volume":"20","author":"AL Deboni","year":"2012","unstructured":"Deboni\u00a0AL, Giordani\u00a0AJ, Lopes\u00a0NNF, Dias\u00a0RS, Segreto\u00a0RA, Jensen\u00a0SB et al (2012) Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer. Support Care Cancer 20(11):2903\u20132911","journal-title":"Support Care Cancer"},{"issue":"14","key":"3504_CR10","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2016.71.8478","volume":"35","author":"L Nekhlyudov","year":"2017","unstructured":"Nekhlyudov\u00a0L, Lacchetti\u00a0C, Davis\u00a0NB, Garvey\u00a0TQ, Goldstein\u00a0DP, Nunnink\u00a0JC et\u00a0al (2017) Head and neck cancer survivorship care guideline: American society of clinical oncology clinical practice guideline endorsement of the American cancer society guideline. J\u00a0Clin Oncol 35(14):1606\u20131621","journal-title":"J Clin Oncol"},{"issue":"6","key":"3504_CR11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.mcna.2017.06.003","volume":"101","author":"N Gegechkori","year":"2017","unstructured":"Gegechkori\u00a0N, Haines\u00a0L, Lin\u00a0JJ (2017) Long-term and latent side effects of specific cancer types. Med Clin North Am 101(6):1053\u20131073","journal-title":"Med Clin North Am"},{"issue":"4","key":"3504_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano\u00a0G, Cardinale\u00a0D, Dent\u00a0S, Criscitiello\u00a0C, Aseyev\u00a0O, Lenihan\u00a0D et\u00a0al (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA A Cancer J Clin 66(4):309\u2013325","journal-title":"CA A Cancer J Clin"},{"issue":"2","key":"3504_CR13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/resp.13915","volume":"25","author":"K Long","year":"2020","unstructured":"Long\u00a0K, Suresh\u00a0K (2020) Pulmonary toxicity of systemic lung cancer therapy. Respirology 25(2):72\u201379","journal-title":"Respirology"},{"issue":"2","key":"3504_CR14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/toxsci\/kfy309","volume":"168","author":"DL Laskin","year":"2019","unstructured":"Laskin\u00a0DL, Malaviya\u00a0R, Laskin\u00a0JD (2019) Role of macrophages in acute lung injury and chronic fibrosis induced by pulmonary toxicants. Toxicol Sci 168(2):287\u2013301","journal-title":"Toxicol Sci"},{"issue":"1","key":"3504_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-5231(03)00123-0","volume":"25","author":"AH Limper","year":"2004","unstructured":"Limper\u00a0AH (2004) Chemotherapy-induced lung disease. Clin Chest Med 25(1):53\u201364","journal-title":"Clin Chest Med"},{"issue":"4","key":"3504_CR16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5306\/wjco.v11.i4.190","volume":"11","author":"MLC Santos","year":"2020","unstructured":"Santos\u00a0MLC, de Brito\u00a0BB, da Silva\u00a0FAF, Botelho\u00a0ACDS, de Melo\u00a0FF (2020) Nephrotoxicity in cancer treatment: an overview. World J Clin Oncol 11(4):190\u2013204","journal-title":"World J Clin Oncol"},{"issue":"6","key":"3504_CR17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3322\/caac.21286","volume":"65","author":"K El-Shami","year":"2015","unstructured":"El-Shami\u00a0K, Oeffinger\u00a0KC, Erb\u00a0NL, Willis\u00a0A, Bretsch\u00a0JK, Pratt-Chapman\u00a0ML et al (2015) American cancer society colorectal cancer survivorship care guidelines. CA A Cancer J Clin 65(6):428\u2013455","journal-title":"CA A Cancer J Clin"},{"issue":"1","key":"3504_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcsm.12127","volume":"8","author":"Mochamat","year":"2017","unstructured":"Mochamat, Cuhls\u00a0H, Marinova\u00a0M, Kaasa\u00a0S, Stieber\u00a0C, Conrad\u00a0R et\u00a0al (2017) A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a\u00a0European palliative care research centre cachexia project. J\u00a0Cachexia Sarcopenia Muscle 8(1):25\u201339","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"3504_CR19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1210\/er.2018-00092","volume":"40","author":"J Gebauer","year":"2019","unstructured":"Gebauer\u00a0J, Higham\u00a0C, Langer\u00a0T, Denzer\u00a0C, Brabant\u00a0G (2019) Long-term endocrine and metabolic consequences of cancer treatment: a systematic review. Endocr Rev 40(3):711\u2013767","journal-title":"Endocr Rev"},{"issue":"6","key":"3504_CR20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3892\/mco.2017.1237","volume":"6","author":"A Imai","year":"2017","unstructured":"Imai\u00a0A, Ichigo\u00a0S, Matsunami\u00a0K, Takagi\u00a0H, Kawabata\u00a0I (2017) Ovarian function following targeted anti-angiogenic therapy with bevacizumab. Mol Clin Oncol 6(6):807\u2013810","journal-title":"Mol Clin Oncol"},{"key":"3504_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00761-022-01100-3","author":"R Dittrich","year":"2020","unstructured":"Dittrich\u00a0R, Lotz\u00a0L, von Wolff\u00a0M (2020) Fertilit\u00e4tserhalt in der Onkologie. Reproduktionsmedizin. https:\/\/doi.org\/10.1007\/s00761-022-01100-3","journal-title":"Reproduktionsmedizin"},{"issue":"5","key":"3504_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12672-016-0274-1","volume":"7","author":"S Casco","year":"2016","unstructured":"Casco\u00a0S, Soto-Vega\u00a0E (2016) Development of metabolic syndrome associated to cancer therapy: review. Horm Cancer 7(5):289\u2013295","journal-title":"Horm Cancer"},{"issue":"3","key":"3504_CR23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.6065\/apem.2040060.030","volume":"25","author":"HY Jin","year":"2020","unstructured":"Jin\u00a0HY, Lee\u00a0JA (2020) Low bone mineral density in children and adolescents with cancer. Ann Pediatr Endocrinol Metab 25(3):137\u2013144","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"1","key":"3504_CR24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-019-0072-5","volume":"5","author":"SG Rockson","year":"2019","unstructured":"Rockson\u00a0SG, Keeley\u00a0V, Kilbreath\u00a0S, Szuba\u00a0A, Towers\u00a0A (2019) Cancer-associated secondary lymphoedema. Nat Rev Dis Primers 5(1):22","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"3504_CR25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00105-013-2625-y","volume":"64","author":"RU Peter","year":"2013","unstructured":"Peter\u00a0RU (2013) Kutanes Strahlensyndrom nach akzidenteller Exposition des Hautorgans mit ionisierenden Strahlen. Hautarzt 64(12):894\u2013903","journal-title":"Hautarzt"},{"issue":"24","key":"3504_CR26","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2217\/fon-2018-0187","volume":"14","author":"J Beech","year":"2018","unstructured":"Beech\u00a0J, Germetaki\u00a0T, Judge\u00a0M, Paton\u00a0N, Collins\u00a0J, Garbutt\u00a0A et al (2018) Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol 14(24):2531\u20132541","journal-title":"Future Oncol"},{"issue":"4","key":"3504_CR27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3897\/folmed.62.e50517","volume":"62","author":"R Strebkova","year":"2020","unstructured":"Strebkova\u00a0R (2020) Cancer-related fatigue in patients with oncological diseases: causes, prevalence, guidelines for assessment and management. Folia Med (Plovdiv) 62(4):679\u2013689","journal-title":"Folia Med (Plovdiv)"},{"issue":"10","key":"3504_CR28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","volume":"11","author":"JE Bower","year":"2014","unstructured":"Bower\u00a0JE (2014) Cancer-related fatigue\u2014mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 11(10):597\u2013609","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3504_CR29","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3390\/ijms20112780","volume":"20","author":"WH Walker 2nd","year":"2019","unstructured":"Walker\u00a0WH 2nd, Borniger\u00a0JC (2019) Molecular mechanisms of cancer-induced sleep disruption. Int J Mol Sci 20(11):2780","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3504_CR30","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","volume":"122","author":"N Donin","year":"2016","unstructured":"Donin\u00a0N, Filson\u00a0C, Drakaki\u00a0A, Tan\u00a0H\u2011J, Castillo\u00a0A, Kwan\u00a0L et al (2016) Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122(19):3075\u20133086","journal-title":"Cancer"},{"issue":"12","key":"3504_CR31","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.3390\/ijerph9124744","volume":"9","author":"S Kumar","year":"2012","unstructured":"Kumar\u00a0S (2012) Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health 9(12):4744\u20134759","journal-title":"Int J Environ Res Public Health"},{"issue":"1\u20132","key":"3504_CR32","first-page":"3","volume":"111","author":"G Schellong","year":"2014","unstructured":"Schellong\u00a0G, Riepenhausen\u00a0M, Ehlert\u00a0K, Br\u00e4mswig\u00a0J, D\u00f6rffel\u00a0W (2014) German working group on the long-term sequelae of Hodgkin\u2019s D, et\u00a0al. Breast cancer in young women after treatment for Hodgkin\u2019s disease during childhood or adolescence\u2014an observational study with up to 33-year follow-up. Dtsch Arztebl Int 111(1\u20132):3\u20139","journal-title":"Dtsch Arztebl Int"},{"issue":"20","key":"3504_CR33","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2016.71.6902","volume":"35","author":"JC Teepen","year":"2017","unstructured":"Teepen\u00a0JC, van Leeuwen\u00a0FE, Tissing\u00a0WJ, van Dulmen-den Broeder\u00a0E, van den Heuvel-Eibrink\u00a0MM, van der Pal\u00a0HJ et al (2017) Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J\u00a0Clin Oncol 35(20):2288\u20132298","journal-title":"J Clin Oncol"},{"issue":"8","key":"3504_CR34","doi-asserted-by":"crossref","first-page":"e1009732","DOI":"10.1371\/journal.pgen.1009732","volume":"17","author":"FS Akhtari","year":"2021","unstructured":"Akhtari\u00a0FS, Green\u00a0AJ, Small\u00a0GW, Havener\u00a0TM, House\u00a0JS, Roell\u00a0KR et al (2021) High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. PLoS Genet 17(8):e1009732","journal-title":"PLoS Genet"},{"issue":"5","key":"3504_CR35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","volume":"10","author":"LB Travis","year":"2013","unstructured":"Travis\u00a0LB, Wahnefried\u00a0WD, Allan\u00a0JM, Wood\u00a0ME, Ng\u00a0AK (2013) Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 10(5):289\u2013301","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3504_CR36","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello\u00a0SM, Barnabei\u00a0A, Marchetti\u00a0P, De Vecchis\u00a0L, Salvatori\u00a0R, Torino\u00a0F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J\u00a0Clin Endocrinol Metab 98(4):1361\u20131375","journal-title":"J Clin Endocrinol Metab"},{"key":"3504_CR37","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.2147\/CMAR.S218756","volume":"12","author":"Q Durrechou","year":"2020","unstructured":"Durrechou\u00a0Q, Domblides\u00a0C, Sionneau\u00a0B, Lefort\u00a0F, Quivy\u00a0A, Ravaud\u00a0A et\u00a0al (2020) Management of immune checkpoint inhibitor toxicities. Cancer Manag Res 12:9139\u20139158","journal-title":"Cancer Manag Res"},{"issue":"1","key":"3504_CR38","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens\u00a0CJ, Goldinger\u00a0SM, Loquai\u00a0C, Robert\u00a0C, Kaehler\u00a0KC, Berking\u00a0C et al (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA\u20114 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8(1):e53745","journal-title":"PLoS One"},{"issue":"2","key":"3504_CR39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain\u00a0L, Walls\u00a0G, Julve\u00a0M, O\u2019Meara\u00a0K, Schmid\u00a0T, Kalaitzaki\u00a0E et al (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a\u00a0single centre experience and review of the literature. Ann Oncol 28(2):377\u2013385","journal-title":"Ann Oncol"},{"issue":"4","key":"3504_CR40","doi-asserted-by":"crossref","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi\u00a0G, Galdiero\u00a0MR, Marone\u00a0G, Criscuolo\u00a0G, Triassi\u00a0M, Bonaduce\u00a0D et\u00a0al (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2(4):e247","journal-title":"ESMO Open"},{"issue":"7","key":"3504_CR41","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1148\/rg.2019190036","volume":"39","author":"KR Kalisz","year":"2019","unstructured":"Kalisz\u00a0KR, Ramaiya\u00a0NH, Laukamp\u00a0KR, Gupta\u00a0A (2019) Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management. Radiographics 39(7):1923\u20131937","journal-title":"Radiographics"},{"issue":"7","key":"3504_CR42","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","volume":"58","author":"SC Weinmann","year":"2019","unstructured":"Weinmann\u00a0SC, Pisetsky\u00a0DS (2019) Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford) 58(7):vii59\u2013vii67","journal-title":"Rheumatology (Oxford)"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-022-03504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-022-03504-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-022-03504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:07:02Z","timestamp":1649074022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-022-03504-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3504"],"URL":"https:\/\/doi.org\/10.1007\/s00103-022-03504-3","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"3 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Ernst und G.\u00a0Schilling geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}